UGT2B7 genetic polymorphisms are associated with the withdrawal symptoms in methadone maintenance patients

Pharmacogenomics

Volumn 13, Issue 8, 2012, Pages 879-888

  Tian, Jia Ni ^a   Ho, Ing Kang ^a   Tsou, Hsiao Hui ^a   Fang, Chiu Ping ^a   Hsiao, Chin Fu ^a   Chen, Chia Hui ^a   Tan, Happy Kuy Lok ^a   Lin, Linen ^a   Wu, Chi Shin ^a   Su, Lien Wen ^a   Huang, Chieh Liang ^a   Yang, Yi Hong ^a   Liu, Ming Lun ^a   Chen, Yu Ting ^a   Liu, Shu Chih ^a   Hsu, Ya Ting ^a   Kuo, Hsiang Wei ^a   Liu, Chen Ting ^a   Yang, Yi Ting ^a   Chen, Andrew C H ^a   Shih, Yu Huei ^a   Liu, Yu Li ^a   more..

^a NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

Author keywords

clinical opioid withdrawal scale; COWS; heroin addiction; methadone; SNP; UGT2B7

Indexed keywords

ADENINE; AMITRIPTYLINE; CYTOSINE; DRUG METABOLITE; GUANINE; METHADONE; THYMINE;

ADULT; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE SEVERITY; DRUG BLOOD LEVEL; FEMALE; GENE; GENETIC ASSOCIATION; GENOTYPE; HAPLOTYPE; HEROIN DEPENDENCE; HUMAN; MAJOR CLINICAL STUDY; MALE; METHADONE TREATMENT; MOLECULAR MODEL; NUCLEOTIDE SEQUENCE; PHARMACOGENETICS; PUPIL; SCORING SYSTEM; SINGLE NUCLEOTIDE POLYMORPHISM; TAIWAN; TREMOR; UGT2B7 GENE; WITHDRAWAL SYNDROME;

ADULT; AMITRIPTYLINE; FEMALE; GENETIC ASSOCIATION STUDIES; GLUCURONOSYLTRANSFERASE; HAPLOTYPES; HEROIN DEPENDENCE; HUMANS; LINKAGE DISEQUILIBRIUM; MALE; METHADONE; MIDDLE AGED; MORPHINE; POLYMORPHISM, SINGLE NUCLEOTIDE; PYRROLIDINES; SUBSTANCE WITHDRAWAL SYNDROME; TAIWAN;

EID: 84862020111     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.12.69     Document Type: Article

References (37)

1. Brown R. Heroin dependence. Wis. Med. J. 103, 20-26 (2004).
2. Pichini S, Altieri I, Pellegrini M, Zuccaro P, Pacifici R. The role of liquid chromatography-mass spectrometry in the determination of heroin and related opioids in biological fluids. Mass Spectrom. Rev. 18(2), 119-130 (1999).
3. Katz N, Hale M, Morris D, Stauffer J. Morphine sulfate and naltrexone hydrochloride extended release capsules in patients with chronic osteoarthritis pain. Postgrad. Med. 122(4), 112-128 (2010).
4. Coffman BL, Rios GR, King CD, Tephly TR. Human UGT2B7 catalyzes morphine glucuronidation. Drug Metab. Dispos. 25(1), 1-4 (1997).
5. Ohno S, Kawana K, Nakajin S. Contribution of UDP-glucuronosyltransferase 1A1 and 1A8 to morphine-6-glucuronidation and its kinetic properties. Drug Metab. Dispos. 36(4), 688-694 (2008). Morphine is also metabolized by liver phase II metabolic isozymes of UGT1A1 and 1A8.
6. Morrish GA, Foster DJ, Somogyi AA. Differential in vitro inhibition of M3G and M6G formation from morphine by (R)- and (S)-methadone and structurally related opioids. Br. J. Clin. Pharmacol. 61(3), 326-335 (2006).
7. Sawyer MB, Innocenti F, Das S et al. A pharmacogenetic study of uridine diphosphate-glucuronosyltransferase 2B7 in patients receiving morphine. Clin. Pharmacol. Ther. 73(6), 566-574 (2003).
8. Stone AN, Mackenzie PI, Galetin A, Houston JB, Miners JO. Isoform selectivity and kinetics of morphine 3- and 6-glucuronidation by human UDP-glucuronosyltransferases: evidence for atypical glucuronidation kinetics by UGT2B7. Drug Metab. Dispos. 31(9), 1086-1089 (2003). UGT2B7 is involved in the catalyzing process of M3G and M6G, which are the morphine metabolites.
9. Mercadante S, Casuccio A, Fulfaro F et al. Switching from morphine to methadone to improve analgesia and tolerability in cancer patients: a prospective study. J. Clin. Oncol. 19(11), 2898-2904 (2001).
10. Gerber JG, Rhodes RJ, Gal J. Stereoselective metabolism of methadone N-demethylation by cytochrome P4502B6 and 2C19. Chirality 16(1), 36-44 (2004).
11. Wang SC, Ho IK, Tsou HH et al. CYP2B6 polymorphisms influence the plasma concentration and clearance of the methadone S-enantiomer. J. Clin. Psychopharmacol. 31(4), 463-469 (2011).
12. Wang JS, Devane CL. Involvement of CYP3A4, CYP2C8, and CYP2D6 in the metabolism of (R)- and (S)-methadone in vitro. Drug Metab. Dispos. 31(6), 742-747 (2003).
13. Crettol S, Deglon JJ, Besson J et al. Methadone enantiomer plasma levels, CYP2B6, CYP2C19, and CYP2C9 genotypes, and response to treatment. Clin. Pharmacol. Ther. 78(6), 593-604 (2005).
14. Trapnell CB, Klecker RW, Jamis-Dow C, Collins JM. Glucuronidation of 3′-azido-3′-deoxythymidine (zidovudine) by human liver microsomes: relevance to clinical pharmacokinetic interactions with atovaquone, fluconazole, methadone, and valproic acid. Antimicrob. Agents Chemother. 42(7), 1592-1596 (1998).
15. Doverty M, Somogyi AA, White JM et al. Methadone maintenance patients are cross-tolerant to the antinociceptive effects of morphine. Pain 93(2), 155-163 (2001).
16. Eugenio KR. Profound morphine tolerance following high-dose methadone therapy. J. Pain Palliat. Care Pharmacother. 18(4), 47-54 (2004).
17. Athanasos P, Smith CS, White JM, Somogyi AA, Bochner F, Ling W. Methadone maintenance patients are cross-tolerant to the antinociceptive effects of very high plasma morphine concentrations. Pain 120(3), 267-275 (2006). In pain perception control, methadone maintenance patients may be cross-tolerant to the analgesic effect of morphine.
18. Marsden J, Farrell M, Bradbury C et al. Development of the treatment outcomes profile. Addiction 103(9), 1450-1460 (2008).
19. Wesson DR, Ling W. The clinical opiate withdrawal scale (COWS). J. Psychoactive Drugs 35(2), 253-259 (2003).
20. Wang SC, Ho IK, Wu SL et al. Development of a method to measure methadone enantiomers and its metabolites without enantiomer standard compounds for the plasma of methadone maintenance patients. Biomed. Chromatogr. 24(7), 782-788 (2009).
21. Rodi CP, Darnhofer-Patel B, Stanssens P, Zabeau M, Van Den Boom D. A strategy for the rapid discovery of disease markers using the MassARRAY system. Biotechniques Suppl.(62-66), 68-69 (2002).
22. Tost J, Gut IG. Genotyping single nucleotide polymorphisms by MALDI mass spectrometry in clinical applications. Clin. Biochem. 38(4), 335-350 (2005).
23. Barrett J, Fry B, Maller J, Daly M. Haploview: ana lysis and visualization of LD and haplotype maps. Bioinformatics 21(2), 263-265 (2005).
24. Stephens M, Donnelly P. A comparison of Bayesian methods for haplotype reconstruction from population genotype data. Am. J. Hum. Genet. 73(5), 1162-1169 (2003).
25. Saeki M, Saito Y, Jinno H et al. Single nucleotide polymorphisms and haplotype frequencies of UGT2B4 and UGT2B7 in a Japanese population. Drug Metab. Dispos. 32(9), 1048-1054 (2004). Discusses the haplotype composition of the UGT2B7 gene in the Japanese population.
26. Yuan HY, Chiou JJ, Tseng WH et al. FASTSNP: an always up-to-date and extendable service for SNP function ana lysis and prioritization. Nucleic Acids Res. 34(Web Server issue), W635-W641 (2006).
27. Gabriel SB, Schaffner SF, Nguyen H et al. The structure of haplotype blocks in the human genome. Science 296(5576), 2225-2229 (2002).
28. Crettol S, Deglon JJ, Besson J et al. ABCB1 and cytochrome P450 genotypes and phenotypes: influence on methadone plasma levels and response to treatment. Clin. Pharmacol. Ther. 80(6), 668-681 (2006).
29. Nielsen S, Hillhouse M, Mooney L, Fahey J, Ling W. Comparing buprenorphine induction experience with heroin and prescription opioid users. J. Subst. Abuse Treat. doi:10.1016/j.jsat.2011.12.009 (2012) (Epub ahead of print).
30. Gunderson EW, Levin FR, Rombone MM, Vosburg SK, Kleber HD. Improving temporal efficiency of outpatient buprenorphine induction. Am. J. Addict. 20(5), 397-404 (2011).
31. Li L, Lin C, Wan D, Zhang L, Lai W. Concurrent heroin use among methadone maintenance clients in China. Addict. Behav. 37(3), 264-268 (2012).
32. Strain EC, Bigelow GE, Liebson IA, Stitzer ML. Moderate vs. high dose methadone in treatment of opiate dependence. JAMA 282(22), 2121-2123 (1999).
33. Hartel DM, Schoenbaum EE, Selwyn PA et al. Heroin use during methadone maintenance treatment: the importance of methadone dose and cocaine use. Am. J. Public Health 85(1), 83-88 (1995).
34. Novick DM, Kreek MJ, Arns PA, Lau LL, Yancovitz SR, Gelb AM. Effect of severe alcoholic liver disease on the disposition of methadone in maintenance patients. Alcoholism (NY) 9(4), 349-354 (1985).
35. National Institutes of Health Clinical Trials. www.clinicaltrial.gov/ct/ show/NCT01059747
36. Guy W. ECDEU Assessment Manual for Psychopharmacology (Revised). US Department of Health, Education, and Welfare, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration, National Institute of Mental Health, Psychopharmacology Research Branch, Division of Extramural Research Programs, Rockville, MD, USA (1976). http://ia700503.us.archive.org/10/items/ ecdeuassessmentm1933guyw/ecdeuassessmentm1933guyw.pdf
37. HapMap. www.hapmap.org/index.html.en